AIM ImmunoTech Management

Management criteria checks 3/4

AIM ImmunoTech's CEO is Thomas Equels, appointed in Aug 2015, has a tenure of 8.67 years. total yearly compensation is $1.08M, comprised of 78.6% salary and 21.4% bonuses, including company stock and options. directly owns 1.44% of the company’s shares, worth $300.91K. The average tenure of the management team and the board of directors is 8.7 years and 7.7 years respectively.

Key information

Thomas Equels

Chief executive officer

US$1.1m

Total compensation

CEO salary percentage	78.6%
CEO tenure	8.7yrs
CEO ownership	1.4%
Management average tenure	8.7yrs
Board average tenure	7.7yrs

Recent management updates

Recent updates

Here's Why We're Not Too Worried About AIM ImmunoTech's (NYSEMKT:AIM) Cash Burn Situation

Feb 28

CEO Compensation Analysis

How has Thomas Equels's remuneration changed compared to AIM ImmunoTech's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$1m	US$850k	-US$29m
Sep 30 2023	n/a	n/a	-US$21m
Jun 30 2023	n/a	n/a	-US$19m
Mar 31 2023	n/a	n/a	-US$19m
Dec 31 2022	US$1m	US$850k	-US$19m
Sep 30 2022	n/a	n/a	-US$21m
Jun 30 2022	n/a	n/a	-US$18m
Mar 31 2022	n/a	n/a	-US$19m
Dec 31 2021	US$2m	US$850k	-US$19m
Sep 30 2021	n/a	n/a	-US$17m
Jun 30 2021	n/a	n/a	-US$17m
Mar 31 2021	n/a	n/a	-US$14m
Dec 31 2020	US$3m	US$807k	-US$14m
Sep 30 2020	n/a	n/a	-US$12m
Jun 30 2020	n/a	n/a	-US$11m
Mar 31 2020	n/a	n/a	-US$10m
Dec 31 2019	US$890k	US$703k	-US$9m
Sep 30 2019	n/a	n/a	-US$10m
Jun 30 2019	n/a	n/a	-US$10m
Mar 31 2019	n/a	n/a	-US$10m
Dec 31 2018	US$1m	US$751k	-US$10m
Sep 30 2018	n/a	n/a	-US$10m
Jun 30 2018	n/a	n/a	-US$8m
Mar 31 2018	n/a	n/a	-US$8m
Dec 31 2017	US$987k	US$713k	-US$8m

Compensation vs Market: Thomas's total compensation ($USD1.08M) is above average for companies of similar size in the US market ($USD677.87K).

Compensation vs Earnings: Thomas's compensation has been consistent with company performance over the past year.

CEO

Thomas Equels (70 yo)

8.7yrs

Tenure

US$1,081,301

Compensation

Mr. Thomas K. Equels, Esq. M.S., J.D. serves as Director at BioFlorida Inc since August 2021. He serves as the Chief Executive Officer of AIM ImmunoTech Inc. (formerly known as Hemispherx Biopharma, Inc.)...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Thomas Equels	Executive Vice Chairman	8.7yrs	US$1.08m	1.44% $ 300.9k
Robert Dickey	Chief Financial Officer	2yrs	US$64.48k	0% $ 0
Peter Rodino	COO, Executive Director of Governmental Relations	7.5yrs	US$527.64k	0.36% $ 76.3k
Ann Marie Coverly	Director of Administration & Human Resources and Deputy Investor Relations Coordinator	11.3yrs	no data	no data
Carol Smith	Chief Manufacturing Officer & Deputy Chief Scientific Officer	31.3yrs	US$171.37k	no data
Christopher McAleer	Scientific Officer	1.3yrs	no data	no data
Ralph Cavalli	Vice President of QC & Manufacturing	14yrs	US$244.00k	no data

8.7yrs

Average Tenure

70yo

Average Age

Experienced Management: AIM's management team is seasoned and experienced (8.7 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Thomas Equels	Executive Vice Chairman	15.4yrs	US$1.08m	1.44% $ 300.9k
Ronald H. Brus	Member of Scientific Advisory Board	no data	no data	no data
William Mitchell	Independent Chairman of the Board & Member of Scientific Advisory Board	25.8yrs	US$139.37k	0.15% $ 32.1k
Christopher Nicodemus	Member of Scientific Advisory Board	no data	no data	no data
Nancy Bryan	Independent Director	1.1yrs	US$93.75k	0.077% $ 16.2k
Stewart Appelrouth	Independent Director	7.7yrs	US$139.37k	0.48% $ 100.7k
W. Burnette	Chairman of Scientific Advisory Board	less than a year	no data	no data
Philip Roane	Member of Scientific Advisory Board	no data	no data	no data

7.7yrs

Average Tenure

69yo

Average Age

Experienced Board: AIM's board of directors are considered experienced (7.7 years average tenure).

AIM ImmunoTech Management

Management criteria checks 3/4

Key information

Recent management updates

AIM ImmunoTech Inc., Annual General Meeting, Dec 29, 2023

AIM ImmunoTech Inc., Annual General Meeting, Dec 01, 2023

AIM ImmunoTech Inc., Annual General Meeting, Dec 01, 2023

Executive Vice Chairman recently bought US$50k worth of stock

AIM ImmunoTech Inc. Promotes Christopher McAleer from Deputy Scientific Officer to Scientific Officer

Insufficient new directors

Recent updates

AIM Immunotech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer

New minor risk - Shareholder dilution

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

AIM ImmunoTech Inc. to Report Q4, 2023 Results on Apr 02, 2024

Price target decreased by 30% to US$2.75

AIM ImmunoTech Inc. announced that it has received $3.30125 million in funding

Aim Immunotech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen for the Treatment of Post-COVID Conditions

AIM ImmunoTech Inc., Annual General Meeting, Dec 29, 2023

AIM ImmunoTech Inc. Completes Treatment of Last Subject in Phase 2 Study Evaluating Ampligen for the Treatment of Post-COVID Conditions

Consensus EPS estimates fall by 12%

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

AIM ImmunoTech Announces Publication of Data from Roswell Park Comprehensive Cancer Center Phase 1 Study Evaluating Ampligen

AIM ImmunoTech Inc. Announces Encouraging Translational Data from Phase 2 Study Evaluating Ampligen for the Treatment of Advanced Recurrent Ovarian Cancer

AIM ImmunoTech Inc., Annual General Meeting, Dec 01, 2023

AIM ImmunoTech Inc., Annual General Meeting, Dec 01, 2023

Kellner Group to Proceed with AIM Director Nominations and Proxy Solicitation

Consensus revenue estimates increase by 15%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

AIM Immunotech Announces Completion of Enrollment in Phase 2 Study Evaluating Ampligen(R) for the Treatment of Post-Covid Conditions

AIM ImmunoTech Enrolls and Doses First Subject in Phase 2 Study Evaluating Ampligen(R) for the Treatment of Post-COVID Conditions

AIM ImmunoTech Inc. Announces Authorizations from Competent Authority and Ethics Board in the Netherlands to Begin Phase 1B/2 Study Evaluating Ampligen®? (Rintatolimod) in Combination with Astrazeneca's Imfinzi (Durvalumab) for the Treatment of Pancreatic Cancer

AIM ImmunoTech Inc. Outlines Recent Significant Progress Across Clinical Development Pipeline and Provides Update on Positive Pre-Clinical and IP Developments

Price target decreased by 7.8% to US$4.92

Price target decreased by 7.7% to US$5.00

First quarter 2023 earnings released: US$0.076 loss per share (vs US$0.08 loss in 1Q 2022)

Consensus revenue estimates decrease by 83%, EPS upgraded

AIM ImmunoTech Inc. Announces the Netherlands Patent Office (Octrooicentrum Nederland) Grants A Utility Patent Covering Rugged dsRNA, A Double-Stranded RNA Product Related to Ampligen® (Rintatolimod)

Executive Vice Chairman recently bought US$50k worth of stock

AIM ImmunoTech Inc. Promotes Christopher McAleer from Deputy Scientific Officer to Scientific Officer

Aim Immunotech Reports Positive Safety, Tolerability and Biological Activity Data for Intranasal Ampligen® (Rintatolimod) in Healthy Subjects

Consensus revenue estimates fall by 34%

Insufficient new directors

AIM ImmunoTech Inc. Announces Presentation of New Data from Roswell Park Comprehensive Cancer Center Evaluating Ampligen

ASFV Committee Issues a Statement on Ruling in Delaware Action

ASFV Committee Reveals Troubling Statements Made by Entrenched AIM Board Uncovered Through Discovery in Delaware Action

Jonathan Thomas Jorgl Issues an Investor Presentation to Shareholders of AIM ImmunoTech

Jonathan Jorgl Provides Information to Shareholders of AIM ImmunoTech

AIM Immunotech Announces FDA Clearance of IND Application to Evaluate Ampligen in Phase 2 Clinical Study for the Treatment of Post-Covid Conditions

Jonathan Thomas Jorgl Mails a Letter to Shareholders of AIM ImmunoTech

AIM ImmunoTech Inc., Annual General Meeting, Nov 03, 2022

AIM ImmunoTech Inc., Annual General Meeting, Nov 03, 2022

AIM ImmunoTech Inc. and Study Collaborator Roswell Park Commence Enrollment in an NCI-Funded Phase 2 Clinical Trial Evaluating Ampligen® (Rintatolimod) in Primary Pd-1/Pd-L1 Resistant Melanoma

Consensus revenue estimates fall by 23%

AIM ImmunoTech Inc. Announces Commencement of Phase 2 Study of Ampligen(R) for the Treatment of Pancreatic Cancer

Jonathan Jorgl Reiterates Intent to Proceed with Nominations and Proxy Solicitation

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

AIM ImmunoTech Reports Positive Pilot Study Data from Expanded Access Program Evaluating Ampligen® for the Treatment of Long COVID

Jonathan Jorgl Provides Information to Shareholders of AIM ImmunoTech Inc

Jonathan Jorgl Provides Information to Shareholders of AIM ImmunoTech Inc

AIM ImmunoTech Reports Additional Patient Data from Single-Center Named Patient Program Evaluating Ampligen as Maintenance Therapy for Advanced Pancreatic Cancer Indicating Additional Progression-Free and Overall Survival over Previously Published Data

Consensus forecasts updated

AIM ImmunoTech Inc. Provides Update on Ampligen Long COVID Development Program

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased to US$7.25

Insufficient new directors

AIM ImmunoTech Provides Summary of Ampligen® Data Supporting Synergistic Potential with Checkpoint Blockade Therapies

Consensus forecasts updated

AIM ImmunoTech Provides Progress on Advancement of Ampligen® Clinical Development Program for the Treatment of Pancreatic Cancer

AIM ImmunoTech Inc. Announces Positive Data from Phase 1 Study Evaluating Ampligen

Full year 2021 earnings: EPS and revenues exceed analyst expectations

AIM ImmunoTech Inc. Announces Executive Changes

Price target decreased to US$6.08

AIM ImmunoTech Inc. Announces Publication of Positive Results from Phase 1/2 Study of Intraperitoneal Chemo-Immunotherapy in Advanced Recurrent Ovarian Cancer

Third quarter 2021 earnings released: US$0.08 loss per share (vs US$0.085 loss in 3Q 2020)

AIM ImmunoTech Submits Pre-IND Application to the FDA for Phase 2 Clinical Studies of Ampligen as a Potential Early-Onset Therapeutic for COVID-19

AIM Immunotech Announces Positive Progress on Requested FDA Meeting for Proposed Ampligen Clinical Trial in Post-Covid-19 Cognitive Dysfunction

AIM ImmunoTech Inc. Provides Status Update on its Pending Phase 2A Human Challenge Trial Using its Drug Ampligen

AIM ImmunoTech Submits Pre-IND Application to the FDA for Phase 2 Clinical Study of Ampligen as a Potential Infusion Therapy for Post-COVID-19 Cognitive Dysfunction

AIM ImmunoTech Announces Filing of Provisional Patent Application for Use of Ampligen as Both an Intranasal and an IV Therapy for Post-COVID-19 Cognitive Dysfunction (PCCD)